Key result
Lower serum adiponectin correlates with more metabolic syndrome components before overt disease onset.
Why the study?
Adiponectin is recognized as a key player in metabolic syndrome, but its relationship with borderline metabolic abnormalities as risk factors for atherosclerotic disease is unclear.
Does serum adiponectin level correlate with metabolic syndrome and borderline metabolic abnormalities in Japanese adults?
Population
16,892 Japanese adults (10,008 men and 6,884 women)
Comparison
Serum adiponectin levels in subjects with metabolic syndrome and borderline metabolic abnormalities versus controls
Design
Cross-sectional study
Authors
Loading...
Adiponectin decline may precede overt MetS; leaves open its role in early risk stratification pending prospective validation.
Cross-Sectional (n=16,892)
No
Does serum adiponectin level correlate with metabolic syndrome and borderline metabolic abnormalities in Japanese adults?
Effect estimate: B = -0.011 (95% CI -0.014 to -0.009)
p-value: p=<0.001
Serum adiponectin levels are inversely correlated not only with metabolic syndrome but also with borderline metabolic abnormalities, suggesting its decline begins early in the development of metabolic dysfunction.
Baden et al. (2011) conducted a cross-sectional in Metabolic syndrome and borderline metabolic abnormalities (n=16,892). Serum adiponectin concentration was evaluated on Number of metabolic syndrome components (B = -0.011, 95% CI -0.014 to -0.009, p=<0.001). Serum adiponectin concentration was significantly negatively correlated with the number of metabolic syndrome components and borderline metabolic abnormalities, indicating adiponectin decreases before overt disease onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: